Personalized medicine for acute myelogenous leukemia-At the entrance gate

American Journal of Hematology

Volumn 86, Issue 8, 2011, Pages 631-632

  Swords, Ronan T ^a   Dezube, Bruce J ^b   Medeiros, Bruno C ^c  

^a CTRC Institute for Drug Development   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEG 35156; ANTINEOPLASTIC AGENT; GEMTUZUMAB OZOGAMICIN; IMATINIB; MLN 4924; QUIZARTINIB; RG 7112; RITUXIMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WILM TUMOR 1 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER STEM CELL; CANCER SURVIVAL; HUMAN; MOLECULAR GENETICS; NOTE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS;

HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY;

EID: 79960374400     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22060     Document Type: Note

References (9)

1. Wang M, Medeiros BC, Erba HP, et al. Targeting protein neddylation: A novel therapeutic strategy for the treatment of cancer. Expert Opin Ther Targets 2011; 15: 253-264.
2. Schimmer AD, Estey EH, Borthakur G, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009; 27: 4741-4746.
3. Berneman ZN, Velde A, Anguille S, et al. WT1-Targeted Dendritic Cell Vaccination as A post-remission treatment to prevent full relapse in acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2010; 116: 16.
4. Andreeff M, Kojima K, Padmanabhan S, et al. A multi-center, open-label, Phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). Blood (ASH Annual Meeting Abstracts). 2010; 116: 657.
5. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984-2992.
6. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of southwest oncology group study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts), 2009; 114: 790.
7. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: Biology and therapeutic targeting. J Clin Oncol 2011; 29: 591-599.
8. Liesveld JL, Bechelli J, Rosell K, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007; 31: 1553-1563.
9. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475-486.